Immatics/$IMTX
1D1W1MYTD1Y5YMAX
Capital at risk
About Immatics
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.
- Ticker
- $IMTX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 704
- Headquarters
- Tübingen, Germany
- Website
- www.immatics.com
Immatics Metrics
BasicAdvanced
$1.2B
-
-$1.86
1.32
-
Price and volume
Market cap
$1.2B
Beta
1.32
52-week high
$12.41
52-week low
$5.67
Average daily volume
593K
Financial strength
Current ratio
7.536
Quick ratio
7.024
Long term debt to equity
2.988
Total debt to equity
3.655
Interest coverage (TTM)
-261.27%
Profitability
EBITDA (TTM)
-253.027
Gross margin (TTM)
-423.73%
Net profit margin (TTM)
-495.27%
Operating margin (TTM)
-543.79%
Effective tax rate (TTM)
0.10%
Revenue per employee (TTM)
$69,630
Management effectiveness
Return on assets (TTM)
-26.92%
Return on equity (TTM)
-47.80%
Valuation
Price to revenue (TTM)
23.396
Price to book
2.99
Price to tangible book (TTM)
3
Price to free cash flow (TTM)
-4.655
Free cash flow yield (TTM)
-21.48%
Free cash flow per share (TTM)
-1.88
Growth
Revenue change (TTM)
-67.95%
Earnings per share change (TTM)
149.44%
3-year revenue growth (CAGR)
-21.08%
3-year earnings per share growth (CAGR)
14.55%
What the Analysts think about Immatics
Analyst ratings (Buy, Hold, Sell) for Immatics stock.
Analyst projections of the future price of Immatics stock.
Immatics Financial Performance
Revenues and expenses
Immatics Earnings Performance
Company profitability
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.